Skip to content
MARKETS / BALCAO / SKVI
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Skinvisible, Inc. SKVI

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$20,000
▲ 0.0% YoY
$-1.1M
$-42,496
In brief

What this company does

Our business model will continue to be to out-license our patented prescription and over-the-counter (“OTC”) products featuring Invisicare to established manufacturers and marketers of brands internationally and to maximize profits from the products we have already out-licensed. On October 17, 2019, we entered an Exclusive License Agreement with Quoin Pharmaceuticals, Inc., a Delaware corporation (“Quoin”) pursuant to which we granted Quoin a license to certain patents for the development of products for commercial sale. Currently, we have two employees, including our Director and CEO Terry Howlett. We conduct our operations through our wholly owned subsidiary, Skinvisible Pharmaceuticals, Inc.

Written from the business description in Skinvisible, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth
USD 20,000.00
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -1.1
0.25M0.50M-0.80M-1.60M201020122014201620182020202220242025
Compound annual growth
−58.5%
−33.4%
−19.5%
−15.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −33.4% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−5320 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -2481.6% · Net -5320.2%
-5000%-10000%201020122014201620182020202220242025
ROE

Not applicable: equity was negative in this period, so return on equity has no meaning.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $
FY2025 · FCF -42496.0
-40000201020122014201620182020202220242025

Total assetsUSD 127,567.00
EquityUSD -10.3M
CashUSD 2,620.00
Current ratio0.01×

Equity funds -8045% of total assets.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B······−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0·
Income tax $B················
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0··············
EPS, diluted $·−0.11−0.52−0.27−0.24−0.32−0.590.01········
Dividend / sh $················
Payout %················
ROE %················
Shares out B0.010.010.000.000.000.000.000.000.00·······

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures · 1 divergences in 67 reconciliationsAUDITED

Reconciled in 15 of 19 fiscal years. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 28 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures1 divergent
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inNevada
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image